The TNF alpha converting enzyme (TACE/ADAM17) is expressed in the atherosclerotic lesions of apolipoprotein E-deficient mice: Possible contribution to elevated plasma levels of soluble TNF alpha receptors

Atherosclerosis

Volumn 187, Issue 1, 2006, Pages 82-91

  Canault, Matthias ^a   Peiretti, Franck ^a   Kopp, Francis ^b   Bonardo, Bernadette ^a   Bonzi, Marie France ^b   Coudeyre, Jean Christophe ^a   Alessi, Marie Christine ^a   Juhan Vague, Irène ^a   Nalbone, Gilles ^a  

^a INSERM   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

Author keywords

Atherosclerosis; Human; Inflammation; Mice; TACE; TNF alpha receptors

Indexed keywords

APOLIPOPROTEIN E; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; TUMOR NECROSIS FACTOR ALPHA RECEPTOR 1; TUMOR NECROSIS FACTOR ALPHA RECEPTOR 2; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA ARCH; AORTA SINUS; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CELL ISOLATION; CELL SURFACE; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIPID DIET; MACROPHAGE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; WILD TYPE;

ADAM PROTEINS; ANIMALS; AORTA; APOLIPOPROTEINS E; ATHEROSCLEROSIS; BONE MARROW CELLS; INTERLEUKIN-6; MACROPHAGES; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MONOCYTES; MYOCARDIUM; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33744797970     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2005.08.031     Document Type: Article

References (45)

1. Mehta J.L., and Li D.Y. Inflammation in ischemic heart disease: Response to tissue injury or a pathogenetic villain?. Cardiovasc Res 43 (1999) 291-299
2. Black R.A., Rauch C.T., Kozlosky C.J., et al. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 385 (1997) 729-733
3. Moss M.L., Jin S.L., Milla M.E., et al. Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha. Nature 385 (1997) 733-736
4. Peiretti F., Canault M., Deprez-Beauclair P., et al. Intracellular maturation and transport of tumor necrosis factor alpha converting enzyme. Exp Cell Res 285 (2003) 278-285
5. Srour N., Lebel A., McMahon S., et al. TACE/ADAM-17 maturation and activation of sheddase activity require proprotein convertase activity. FEBS Lett 554 (2003) 275-283
6. Endres K., Anders A., Kojro E., et al. Tumor necrosis factor-alpha converting enzyme is processed by proprotein-convertases to its mature form which is degraded upon phorbol ester stimulation. Eur J Biochem 270 (2003) 2386-2393
7. Peschon J.J., Slack J.L., Reddy P., et al. An essential role for ectodomain shedding in mammalian development. Science 282 (1998) 1281-1284
8. Solomon K.A., Pesti N., Wu G., et al. Cutting edge: a dominant negative form of TNF-alpha converting enzyme inhibits proTNF and TNFRII secretion. J Immunol 163 (1999) 4105-4108
9. Reddy P., Slack J.L., Davis R., et al. Functional analysis of the domain structure of tumor necrosis factor- alpha converting enzyme. J Biol Chem 275 (2000) 14608-14614
10. Mezyk R., Bzowska M., and Bereta J. Structure and functions of tumor necrosis factor-alpha converting enzyme. Acta Biochim Pol 50 (2003) 625-645
11. Barath P., Fishbein M.C., Cao J., et al. Detection and localization of tumor necrosis factor in human atheroma. Am J Cardiol 65 (1990) 297-302
12. Rus H.G., Niculescu F., and Vlaicu R. Tumor necrosis factor-alpha in human arterial wall with atherosclerosis. Atherosclerosis 89 (1991) 247-254
13. Tipping P.G., and Hancock W.W. Production of tumor necrosis factor and interleukin-1 by macrophages from human atheromatous plaques. Am J Pathol 142 (1993) 1721-1728
14. Ridker P.M., Rifai N., Pfeffer M., et al. Elevation of tumor necrosis factor-{alpha} and increased risk of recurrent coronary events after myocardial infarction. Circulation 101 (2000) 2149-2153
15. Skoog T., Dichtl W., Boquist S., et al. Plasma tumor necrosis factor-alpha and early carotid atherosclerosis in healthy middle-aged men. Eur Heart J 23 (2002) 376-383
16. Jovinge S., Hamsten A., Tornvall P., et al. Evidence for a role of tumor necrosis factor alpha in disturbances of triglyceride and glucose metabolism predisposing to coronary heart disease. Metabolism 47 (1998) 113-118
17. Bruunsgaard H., Skinhoj P., Pedersen A.N., et al. Ageing, tumour necrosis factor-alpha (TNF-alpha) and atherosclerosis. Clin Exp Immunol 121 (2000) 255-260
18. Hurlimann D., Forster A., Noll G., et al. Anti-tumor necrosis factor-{alpha} treatment improves endothelial function in patients with rheumatoid arthritis. Circulation 106 (2002) 2184-2187
19. Popa C., Netea M.G., Radstake T., et al. Influence of anti-TNF treatment on the cardiovascular risk factors in patients with active rheumatoid arthritis. Ann Rheum Dis 2004: Ard. (2004) 023119
20. Elhage R., Maret A., Pieraggi M.-T., et al. Differential effects of interleukin-1 receptor antagonist and tumor necrosis factor binding protein on fatty-streak formation in apolipoprotein E-deficient mice. Circulation 97 (1998) 242-244
21. Niemann-Jonsson A., Dimayuga P., Jovinge S., et al. Accumulation of LDL in rat arteries is associated with activation of tumor necrosis factor-alpha expression. Arterioscler Thromb Vasc Biol 20 (2000) 2205-2211
22. Li A.C., Brown K.K., Silvestre M.J., et al. Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J Clin Invest 106 (2000) 523-531
23. -/- mice. FASEB J 15 (2001) 2730-2732
24. Zhou Z., Lauer M.A., Wang K., et al. Effect of anti-tumor necrosis factor-alpha polyclonal antibody on restenosis after balloon angioplasty in a rabbit atherosclerotic model. Atherosclerosis 161 (2002) 153-159
25. Canault M., Peiretti F., Mueller C., et al. Exclusive expression of transmembrane TNF-[alpha] in mice reduces the inflammatory response in early lipid lesions of aortic sinus. Atherosclerosis 172 (2004) 211-218
26. Branen L., Hovgaard L., Nitulescu M., et al. Inhibition of tumor necrosis factor-{alpha} reduces atherosclerosis in apolipoprotein E knockout mice. Arterioscler Thromb Vasc Biol 24 (2004) 2137-2142
27. Boesten L.S., Zadelaar A.S., van Nieuwkoop A., et al. Tumor necrosis factor-alpha promotes atherosclerotic lesion progression in APOE*3-leiden transgenic mice. Cardiovasc Res 66 (2005) 179-185 Epub 2005 Jan 28
28. Ohta H., Wada H., Niwa T., et al. Disruption of tumor necrosis factor-[alpha] gene diminishes the development of atherosclerosis in ApoE-deficient mice. Atherosclerosis 180 (2005) 11-17
29. Hansen P.R., Chew M., Zhou J., et al. Freunds adjuvant alone is antiatherogenic in apoE-deficient mice and specific immunization against TNFalpha confers no additional benefit. Atherosclerosis 158 (2001) 87-94
30. Schreyer S.A., Vick C.M., and LeBoeuf R.C. Loss of lymphotoxin-alpha but not tumor necrosis factor-alpha reduces atherosclerosis in mice. J Biol Chem 277 (2002) 12364-12368
31. Beck G., Bottomley G., Bradshaw D., et al. (E)-2(R)-[1(S)-(Hydroxycarbamoyl)-4-phenyl-3-butenyl]-2′-isobutyl- 2′-(methanesulfonyl)-4-methylvalerohydrazide (Ro 32-7315), a selective and orally active inhibitor of tumor necrosis factor-alpha convertase. J Pharmacol Exp Ther 302 (2002) 390-396
32. Reddick R.L., Zhang S.H., and Maeda N. Atherosclerosis in mice lacking apo E. Evaluation of lesional development and progression. Arterioscler Thromb 14 (1994) 141-147
33. Csiszar A., Ungvari Z., Koller A., et al. Proinflammatory phenotype of coronary arteries promotes endothelial apoptosis in aging. Physiol. Genomics 17 (2004) 21-30
34. Jovinge S., Ares MPS, Kallin B., et al. Human monocytes/macrophages release TNF-{alpha} in response to Ox-LDL. Arterioscler Thromb Vasc Biol 16 (1996) 1573-1579
35. Rovida E., Paccagnini A., Del Rosso M., et al. TNF-{{alpha}}-converting enzyme cleaves the macrophage colony-stimulating factor receptor in macrophages undergoing activation. J Immunol 166 (2001) 1583-1589
36. Ermert M., Pantazis C., Duncker H.-R., et al. In situ localization of TNF[alpha]/[beta], TACE and TNF receptors TNF-R1 and TNF-R2 in control and LPS-treated lung tissue. Cytokine 22 (2003) 89-100
37. Akatsu T., Nakamura M., Satoh M., et al. Increased mRNA expression of tumour necrosis factor-alpha and its converting enzyme in circulating leucocytes of patients with acute myocardial infarction. Clin Sci (Lond) 105 (2003) 39-44
38. Satoh M., Iwasaka J., Nakamura M., et al. Increased expression of tumor necrosis factor-alpha converting enzyme and tumor necrosis factor-alpha in peripheral blood mononuclear cells in patients with advanced congestive heart failure. Eur J Heart Fail 6 (2004) 869-875
39. Aderka D. The potential biological and clinical significance of the soluble tumor necrosis factor receptors. Cytokine Growth Factor Rev 7 (1996) 231-240
40. Porsch-Oezcueruemez M., Kunz D., Kloer H.-U., et al. Evaluation of serum levels of solubilized adhesion molecules and cytokine receptors in coronary heart disease. J Am Coll Cardiol 34 (1999) 1995-2001
41. Benjafield A.V., Wang X.L., and Morris B.J. Tumor necrosis factor receptor 2 gene (TNFRSF1B) in genetic basis of coronary artery disease. J Mol Med 79 (2001) 109-115
42. Valgimigli M., Ceconi C., Malagutti P., et al. Tumor necrosis factor-{alpha} receptor 1 is a major predictor of mortality and new-onset heart failure in patients with acute myocardial infarction: the cytokine-activation and long-term prognosis in myocardial infarction (C-ALPHA) study. Circulation 111 (2005) 863-870
43. Douni E., and Kollias G. A Critical Role of the p75 Tumor necrosis factor receptor (p75TNF-R) in organ inflammation independent of TNF, lymphotoxin alpha, or the p55TNF-R. J Exp Med 188 (1998) 1343-1352
44. Newton R.C., Solomon K.A., Covington M.B., et al. Biology of TACE inhibition. Ann Rheum Dis 60 (2001) 25-32
45. Canault M., Peiretti F., Mueller C., et al. Proinflammatory properties of murine aortic endothelial cells exclusively expressing a non-cleavable form of TNFalpha. Effect on tumor necrosis factor alpha receptor type 2. Thromb Haemost 92 (2004) 1428-1437